ATYR News

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR

ATYR

(NASDAQ:ATYR) LOS ANGELES--(BUSINESS WIRE)---- $ATYR--aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR

September 15, 2025Legal
Read more →

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update

ATYR

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update

August 7, 2025Earnings
Read more →

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

ATYR

June 4, 2025
Read more →

aTyr Pharma Announces Findings From Interim Analysis Of Eight Patients In Ongoing Phase 2 EFZO-CONNECT Study Evaluating Efzofitimod In SSc-ILD Patients

ATYR

June 4, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

ATYR

May 19, 2025
Read more →

aTyr Pharma Advances ATYR0101 To IND Candidate Stage For Pulmonary Fibrosis; Preclinical Data Demonstrate ATYR0101's Unique Anti-fibrotic Mechanism Through Interaction With LTBP-1

ATYR

May 14, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

ATYR

March 14, 2025
Read more →

Atyr Pharma Announces A Publication Demonstrating The Mechanism Of Action For Its Lead Therapeutic Candidate, Efzofitimod, In The Journal Science Translational Medicine

ATYR

March 12, 2025
Read more →

aTyr Pharma Announces Fourth DSMB Review For Efzofitimod In Phase 3 EFZO-FIT Study In Pulmonary Sarcoidosis

ATYR

March 6, 2025
Read more →

This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

ATYR

February 18, 2025
Read more →

Leerink Partners Initiates Coverage On aTyr Pharma with Outperform Rating, Announces Price Target of $16

ATYR

February 18, 2025
Read more →

aTyr Pharma To Present Poster sOn ATYR0101 At Keystone Symposia on Fibrosis Dec. 8-11

ATYR

November 15, 2024
Read more →